Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQB4VN)

• Drug Name: MGD006 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 1	[1]
Acute myeloid lymphoma	2A80	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQB4VN

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[6]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[7]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[8]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[9]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[10]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[11]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[12]

Drug(s) Targeting Interleukin 3 receptor alpha (IL3RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tagraxofusp	DM9HQ5U	Acute myeloid leukaemia	2A60	Approved	[13]
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[14]
Talacotuzumab	DMARVFG	Acute myeloid leukaemia	2A60	Phase 2	[15]
MB-102	DMLPNVS	Acute kidney injury	GB60	Phase 2	[15]
Flotetuzumab	DMVR6OM	Acute biphenotypic leukaemia	2B33.4	Phase 2	[15]
4SCAR19 and 4SCAR123	DMYPQT4	B-cell lymphoma	2A86	Phase 1/2	[16]
SAR440234	DM6M8O4	Acute myeloid leukaemia	2A60	Phase 1/2	[17]
CD123-specific gene-engineered T cells	DMHOWU5	Acute myeloid leukaemia	2A60	Phase 1/2	[18]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[19]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	Modulator	[2]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Modulator	[1]

References

• [1] A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
• [2] A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] Clinical pipeline report, company report or official report of Genmab.
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [7] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [8] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [9] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [10] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [11] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [12] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [17] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [18] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [19] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [20] ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML